This protocol applies to primary breast lymphoma (PBL) presenting as the Burkitt lymphoma histological subtype — among the rarest variants of this disease category.
Given the aggressive biology of PB-BL, management may involve surgical and/or intensive systemic chemotherapy, with the specific strategy individualized to patient circumstances. The therapeutic goal is complete remission of the breast lymphoma.
Primary breast Burkitt lymphoma (PB-BL) is one of the rarest histological variants of PBL, although its growth is extremely rapid and aggressive and can be fatal if not diagnosed early and treated appropriately.
Successful PB-BL treatment outcomes have been achieved with bilateral mastectomy followed by adjuvant chemotherapy, although due to the aggressive nature of PB-BL, most cases require an intensive chemotherapy regimen.
View source ↗